Sanofi Sa Stock Gross Profit

SAN Stock  EUR 104.84  0.14  0.13%   
Sanofi SA fundamentals help investors to digest information that contributes to Sanofi SA's financial success or failures. It also enables traders to predict the movement of Sanofi Stock. The fundamental analysis module provides a way to measure Sanofi SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi SA stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sanofi SA Company Gross Profit Analysis

Sanofi SA's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Sanofi SA Gross Profit

    
  31.7 B  
Most of Sanofi SA's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Sanofi SA reported 31.7 B of gross profit. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The gross profit for all France stocks is 15.78% lower than that of the firm.

Sanofi Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi SA's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi SA could also be used in its relative valuation, which is a method of valuing Sanofi SA by comparing valuation metrics of similar companies.
31.7B27.7B9.2B27.7B100%
Sanofi SA is currently under evaluation in gross profit category among its peers.

Sanofi Fundamentals

About Sanofi SA Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sanofi SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Sanofi Stock

Sanofi SA financial ratios help investors to determine whether Sanofi Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sanofi with respect to the benefits of owning Sanofi SA security.